-
Synagis
- Gen: Palivizumab,
- Class: Immunological Agent, (Mab) RSV-I,
- RoA: IM,
- MOA: exhibits neutralizing and fusion-inhibitory activity, Indication: Repiratory syncytial virus infection (RSV)
-
Zofran
- Gen: Ondansetron,
- Class: 5-HT3 Antagonist, Antiemetic,
- RoA: Oral,
- MOA: blocking 5-HT3 peripherally on vagal nerve terminal in CTZ (chemoreceptor trigger zone),
- Indication: Chemotherapy/Radiation N/V, postoperative
-
Prilosec
- Gen: Omeprazole
- Class: PPI
- RoA: Oral
- MOA: inhibits acid secretion by covalently binding H/K ATPase pumps
- Indication: DU, GU, GERD, erosive esophagitis, gastric hypersecretion
-
Rocephin
- Gen: Ceftriaxone Sodium
- Class: Antibiotic (3rd Gen cephalosporin),
- RoA: IV
- MOA: inhibition of cell-wall synthesis
- Indication: UTI, LRTI, gonorrhea,
-
Zemuron
- Gen: Rocuronium Bromide
- Class: Neuromuscular Blocker, Musculoskeletal agent
- RoA: IV
- MOA: competes for cholinergic receptors at the motor end-plate
- Indication: General anesthesia
-
Alimta
- Gen: Pemetrexed
- Class: Antineoplastic Agent (DHFR-I), pyrrolopyrimidine
- RoA: IV infusion
- MOA: disrupts folate-dependent metabolic processes for cell replication
- Indication: mesothelioma, small cell lung cancer
-
Maxipime
- Gen: Cefepime Hydrochloride
- Class: Antibiotic (4th Gen Cephalosporin)(PBP)
- RoA: IV
- MOA: inhibits cell wall synthesis
- Indication: Pneumonia, UTI, infections
-
Novoseven
- Gen: Coagulation Factor VIIA
- Class: Hemostatic (coagulant)
- RoA: IV
- MOA: promotes hemostasis by complexing tissue factor activating coagulation facotrs in intrinsic pathway
- Indication: Hemophilia, Factor VII, VIII deficiency
-
Lantus
- Gen: Insulin Glargine, Recombinant
- Class: Antidiabetic (long acting insulin)
- RoA: SC
- MOA: Stimulates glucose uptake by muscle
- Indication: Diabetes mellitus type 1 & 2
-
Optiray 320
- Gen: Ioversol
- Class: non radial contrast agent
- RoA: IV
- MOA:
- Indication: diagnostic radiology
-
Activase
- Gen: Alteplase, Recombinant
- Class: Thromolytic, Tissue Plasminogen Activator (TPA)(anti-coagulant)
- RoA: IV
- MOA: enhances plasminogen to plasmin by binding fibrin initiating fibrinolysis,
- Indication: Acute MI & Ischemia, PE, venous catheter occlusion
|
|
